Anti-lipid oligoclonal IgM bands contribute to progressive multifocal leukoencephalopathy (PML) risk stratification in multiple sclerosis patients treated with natalizumab

dc.contributor.author	Villar, L.
dc.contributor.author	Costa-Frossard, L.
dc.contributor.author	Tuñón Álvarez, Alberto
dc.date.accessioned	2014-04-04T08:14:32Z
dc.date.available	2014-04-04T08:14:32Z
dc.date.issued	2013
dc.identifier.issn	1352-4585
dc.identifier.issn	1477-0970
dc.identifier.uri	http://hdl.handle.net/10651/25262
dc.description	Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (29th, 2013, Copenhagen)
dc.description.statementofresponsibility	Villar, L., Costa-Frossard, L., Fernández, O., Montalbán, X., Casanova, B., Izquierdo, G., Masterman, T., Coret, F., Tumani, H., Saiz, A., Arroyo, R., Leyva, L., Espejo, C., García-Sánchez, MI., Fink, K., Lauda, F., Llufriu, S., Álvarez-Lafuente, R., Olascoaga, J., Oterino, A., De Andrés, C., García-Merino, J.A., Landete, L., Menéndez, M., Navarro, L., Pérez, D., Ramio, L., Tunón, A., Álvarez-Cermeno, J.C.
dc.format.extent	p. 56-57
dc.language.iso	eng
dc.relation.ispartof	Multiple Sclerosis Journal, 19(11)
dc.rights	©,
dc.source	WOS:000328751400087
dc.title	Anti-lipid oligoclonal IgM bands contribute to progressive multifocal leukoencephalopathy (PML) risk stratification in multiple sclerosis patients treated with natalizumab
dc.type	conference output	spa
dc.identifier.local	20141123
dc.identifier.doi	10.1177%2F1352458513502433
dc.relation.publisherversion	https://doi.org/10.1177%2F1352458513502433

Ficheros en el ítem

Ficheros	Tamaño	Formato	Ver
No hay ficheros asociados a este ítem.